United States · 
What does ARCH Venture Partners invest in?
ARCH Venture Partners invests most often at Series A and Series B (61% of the rounds on record), in sectors such as Information Technology, Life Sciences and Physical Sciences.
ARCH Venture Partners highlights
- 01
41 cheques in the last 12 months
- 02
Mostly Series A and Series B: 61% of its rounds
- 03
Sole investor in 17 rounds, median $18M
- 04
19 exits from the portfolio
What they do
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciencesFrom their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- $50K – $150M as they say
- Stages
- SeedSeries ASeries BGrowth
- Sectors
- Information TechnologyLife SciencesPhysical Sciences
- Based in
- Chicago, United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first337 appearances
- 2026
31 rounds
- Oct
- Oct
- Sept
- Sept
- Sept
- Jul
- Jul
- Jun
- Jun
- Jun
- Jun
- Jun
- Jun
- May
- May
- May
- Apr
- Apr
- Apr
- Mar
- Mar
- Mar
- Feb
- Feb
- Feb
- Feb
- Jan
- Jan
- Jan
- Jan
- Jan
- 2025
34 rounds
- Dec
- Dec
- Dec
- Dec
- Nov
- Nov
- Nov
- Nov
- Nov
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration9 named
CWClinton Whitewood BybeeManaging Director of the General Partner.iFiling they signed
JLJason L. DorenGeneral Counsel of the GP LLCiFiling they signed
KLKeith Lawrence CrandellManaging Director, President, Secretary and ShareholderiForm ADV
KMKristina Marie BurowManaging Director, Vice President, and ShareholderiForm ADV
MAMark Andrew McdonnellManaging Director of the General Partner.iFiling they signed
PTPaul T. BernsManaging Director of the GP LLCiFiling they signed
PTPaul T. ThurkManaging Director of the General Partner.iFiling they signed
RTRobert Taylor NelsenManaging Director of the General Partner.iFiling they signed
SLSteven L. GillisManaging Director of the General PartneriFiling they signed
We also hold 56 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$11Bgross assets of its fundsOct 2026
Exemptreporting adviserventure or small private funds
- Legal name
- ARCH Venture Management LLC
- SEC number
- CRD 158196
Who backs their funds
1 LP on record in ARCH Venture Partners's funds
- Committed
- $30M
- Funds
- 1
- Vintages
- 2004
The institutions that put money into its funds, which the firm then invests in companies.Source: the pension's own report, latest Jun 2025.
- California State Teachers Retirement System1 fund$30M
Fund Vintage Committed ARCH Venture Fund VI 2004 $30M
What they claim to have backed
From their own portfolio page (on their website)
60 of 60 we have independently watched raise
908 DevicesAccompany HealthAgios PharmaceuticalsAkamis BioAledadeAltos LabsArbor BiotechnologiesArraybiopharmaArsenal BiosciencesAspen NeuroscienceBE BiopharmaBasking BiosciencesBluebirdbioBoundlessbioBrii BiosciencesCStone PharmaceuticalsCarricktherapeuticsCytrellis BiosystemsDenali TherapeuticsEncoded TherapeuticsErascaFaraday PharmaceuticalsGate BioscienceGenerate BiomedicinesGossamerbioHiberCellHomologymedicinesHuamedicineJW TherapeuticsJaguar Gene TherapyKardiganKura OncologyLifordi ImmunotherapeuticsLightcast DiscoveryMagnet BiomedicineMatter NeuroscienceMoonwalk BiosciencesONIOmniome (Acquired)OneBioMedParabilis MedicinesPheast TherapeuticsProtillion BiosciencesQihan BiotechQuantum CircuitsRIPPL CareReceptosRecuro HealthScholarrockSingleron BiotechnologiesSlingshot BiosciencesSunBird BioSynchronTreeline BiosciencesTwist BioscienceUltivueUnitybiotechnologyVir BiotechnologyVividionVizgenand 39 more
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed19 in all
Kythera BiopharmaceuticalsBought by Allergan$2.1BJun 2015
IkariaBought by Mallinckrodt$2.3BMar 2015
NextCode HealthBought by WuXi PharmaTech (Cayman)$65MJan 2015
NitronexBought by M/A-COM Technology Solutions$26MFeb 2014
KOTURABought by Mellanox Technologies$82MAug 2013
bluebird bioListed$101MJun 2013
Agios PharmaceuticalsListed$86MJun 2013
InnovalightBought by DuPontUndisclosedJul 2011
Surface LogixBought by Nano TerraUndisclosedApr 2011
Ahura ScientificBought by Thermo Fisher Scientific$145MJan 2010
OmerosListedUndisclosedOct 2009
Amphora DiscoveryBought by NanosynUndisclosedJul 2008
Univa UDBought by Univa UDUndisclosedOct 2007
Vascular ArchitectsBought by LeMaitre VascularUndisclosedSept 2007
NeurogesXListedUndisclosedFeb 2007
SilverStorm TechnologiesBought by QLogicUndisclosedOct 2006
NexCuraBought by The Thompson CorporationUndisclosedNov 2005
Teach.comBought by IntellinexUndisclosedOct 2000
An exit counts when it came after the firm's first round in the company. From historical deal records.